# Project Status


Phase 11I-A Final QA and Journal-Specific Gap Audit completed on 2026-07-04. The submission package was verified for completeness, callout consistency, and strict adherence to claim-control constraints (e.g., non-causal microbiome assertions). Journal-specific formatting items have been cataloged as gaps to be resolved once the target journal is confirmed. The final readiness decision is **`READY_FOR_TARGET_JOURNAL_SELECTION`**.

Phase 11H Submission Package Assembly completed on 2026-07-04. Created generic cover letter, submission checklist, package inventory, missing items log, and copied all required manuscript, bibliography, figures, and tables. Final decision is PASS. The final readiness decision is **`READY_FOR_TARGET_JOURNAL_SELECTION`**.

Post-Phase 11G workspace cleanup finalization completed on 2026-07-04. Audited and deleted temporary agent utility scripts, and safely ignored intermediate data models. The final readiness decision is **`READY_FOR_TARGET_JOURNAL_SELECTION`**.

Phase 11G administrative finalization completed on 2026-07-04. Phase 11G, Phase 11G-R1b, Phase 11G-R2, and Phase 11G-R3 have completed. The final Phase 11G-R3 decision is PASS. Manuscript scientific content was not changed beyond citation/callout/reference-number repair, and evidence categories and target rankings were unchanged. The final readiness decision is **`READY_FOR_TARGET_JOURNAL_SELECTION`**.

Phase 11F final claim audit completed on 2026-07-04. The independent audit verified that the Phase 11E language-edited manuscript maintained all computational evidence constraints without biological overstatement. Evidence categories and target rankings were unmodified, microbial causality and localisation remain explicitly denied, and null findings remain visible. The final readiness decision is **`READY_FOR_TARGET_JOURNAL_SELECTION`**.

Phase 11E language and format review completed on 2026-07-04. The review improved readability, paragraph flow, and terminology consistency across all sections, while strictly preserving all prior epistemic constraints and claim-control boundaries (non-causal microbial associations, partial spatial support for protein secretion, and composition-based target scoring penalties). The final readiness decision is **`READY_FOR_TARGET_JOURNAL_SELECTION`**.

Phase 9B3R corrected spatial-transcriptomic validation reanalysis completed on 2026-07-04. We reran the failed Phase 9B3B spatial validation under the Phase 9B3R0 repair specification, replaced placeholder negative controls with real empirical null distributions, enforced feature eligibility before model fitting, retained nonconverged models only as NA audit rows, documented the locked statsmodels asymptotic Z inference, and derived evidence categories programmatically. The final readiness decision is **`READY_FOR_PHASE9B3C2_COMPLETE_INDEPENDENT_REVIEW`**.

Phase 9B3C spatial-transcriptomic validation independent review completed on 2026-07-04. We have performed a full independent review of the executed Phase 9B3B spatial validation. The audit identified critical execution failures (hardcoded negative control placeholders), major model violations (retention of non-converged treated cohort Model C), and eligibility violations (fitting models for the low-coverage feature HALLMARK_SPERMATOGENESIS). The final decision is **`FAIL_REQUIRES_REANALYSIS`**.

Phase 9B3A.2 spatial-transcriptomic validation planning final hierarchy correction completed on 2026-07-03. We have locked the Hwang GeoMx ROI pairing models (Model A, B, and C), reclassified Moncada ST as exploratory cross-platform spatial consistency (due to low patient sample size n=2), and strictly enforced the cross-platform matrix pooling ban. All validators run and pass.

Phase 9B3A.1 spatial-transcriptomic validation design consistency correction completed on 2026-07-03. We have reconciled Hypothesis 3 lymphoid adjustment, locked nested linear mixed-effects model (LMM) random-effect structures for each cohort, resolved patient/section count ambiguities, and locked a reduced-model fallback hierarchy.

## Completed Tasks


- Completed Phase 11I-A Final QA and Journal-Specific Gap Audit.
- Created `04_analysis/11_manuscript/PHASE11IA_FINAL_QA_AND_JOURNAL_GAP_AUDIT.md`, `phase11ia_final_qa_checklist.tsv`, and `phase11ia_journal_specific_gap_table.tsv`.
- Validated package completeness and claim-control constraints, identifying 11 TO_BE_CONFIRMED journal gaps.
- Completed Phase 11A manuscript structure, claim-control, and figure/table planning.
- Created PHASE11A_MANUSCRIPT_CLAIM_MAP.md and PHASE11A_MANUSCRIPT_OUTLINE.md.
- Created phase11a tables for claim map, figures, and prohibited claims.
- Validated manuscript plan using python3 06_scripts/python/19_validate_phase11a_manuscript_plan.py.

- Completed Phase 9B3R corrected spatial validation reanalysis and created `04_analysis/09_external_validation/PHASE9B3R_CORRECTED_SPATIAL_VALIDATION_RESULTS.md`.
- Created `04_analysis/09_external_validation/PHASE9B3R_CORRECTION_LOG.md` and marked `PHASE9B3B_SPATIAL_VALIDATION_RESULTS.md` as `SUPERSEDED_BY_PHASE9B3R`.
- Generated corrected `phase9b3r_` tables and figure, including iteration-level negative-control null distributions.
- Created corrected execution, validation, manifest-update, and pytest scripts for Phase 9B3R.
- Completed Phase 9B3C spatial-transcriptomic validation independent review, provenance audit, ROI pairing check, model convergence audit, feature eligibility checks, and negative control verification.
- Created independent review report `04_analysis/09_external_validation/PHASE9B3C_SPATIAL_VALIDATION_INDEPENDENT_REVIEW.md`.
- Generated audit and findings tables under `05_results/tables/`: cohort count, ROI pairing, model reproduction, feature eligibility, negative control, evidence category, and review findings.
- Completed Phase 9B3A.2 spatial-transcriptomic validation planning final hierarchy correction, ROI pairing model locks, and Moncada exploratory reclassification.
- Created final correction report `04_analysis/09_external_validation/PHASE9B3A2_SPATIAL_HIERARCHY_FINAL_CORRECTION.md` and Model Hierarchy table `05_results/tables/phase9b3a2_spatial_model_hierarchy.tsv`.
- Completed Phase 9B3A.1 spatial-transcriptomic validation design consistency correction and terminology reconciliation (LMM).
- Generated spatial analysis unit and models table `05_results/tables/phase9b3a1_spatial_analysis_unit_and_models.tsv` and helper script `06_scripts/python/generate_phase9b3a1_tables.py`.
- Created spatial design consistency report `04_analysis/09_external_validation/PHASE9B3A1_SPATIAL_DESIGN_CONSISTENCY_CORRECTION.md`.
- Completed Phase 9B3A spatial-transcriptomic validation planning, dataset qualification, feature hierarchy locking, and prospective statistical-design locking.
- Created spatial method lock document `04_analysis/09_external_validation/PHASE9B3A_SPATIAL_VALIDATION_METHOD_LOCK.md` and spatial protocol `09_docs/methods/PDAC_spatial_validation_protocol.md`.
- Generated spatial planning inventory and parameters in `01_metadata/phase9b3_spatial_dataset_inventory.tsv` and `01_metadata/phase9b3_spatial_parameter_inventory.tsv`.
- Generated spatial feature hierarchy, qualification, authoritative cohort set, and resource estimates under `05_results/tables/`.
- Created and successfully executed spatial plan validator `06_scripts/python/16_validate_phase9b3a_spatial_plan.py`.
- Completed Phase 9B2R consolidated corrective single-cell reanalysis on `PENG_CRA001160` only.
- Created `04_analysis/09_external_validation/PHASE9B2R_CORRECTION_LOG.md` and `PHASE9B2R_CORRECTED_SINGLE_CELL_CELLULAR_SOURCE_RESULTS.md`.
- Created corrected Phase 9B2R scripts: `06_scripts/R/15_phase9b2r_corrected_single_cell_validation.R`, `06_scripts/python/15_prepare_phase9b2r_single_cell.py`, and `06_scripts/python/15_validate_phase9b2r_single_cell.py`.
- Generated corrected Phase 9B2R coverage, negative-control, TF classification, malignant-axis, cellular-source evidence, composition, tumor-control, verification, and figure outputs.
- Ran `python3 06_scripts/python/15_prepare_phase9b2r_single_cell.py` and `python3 06_scripts/python/15_validate_phase9b2r_single_cell.py` successfully.
- Completed Phase 9B2C independent statistical, implementation, annotation, and evidence review of the primary single-cell cellular-source analysis on PENG_CRA001160.
- Logged mandatory skill usages (exploratory-data-analysis, experimental-design, and statistical-analysis) in `00_admin/SKILL_USAGE_LOG.tsv`.
- Generated Phase 9B2C independent review tables under `05_results/tables/`: annotation audit, malignant cell audit, pseudobulk audit, feature evidence audit, negative control audit, and review findings.
- Registered all 7 Phase 9B2C review outputs in `01_metadata/file_manifest.tsv`.
- Appended D-38 and D-39 decisions to `09_docs/planning/DECISION_LOG.md`.
- Programmatically ran provenance and manifest consistency checks, validating agreement across tables.

- Verified project root at `~/thesis/PDAC`.
- Verified existing scaffold and scripts.
- Confirmed environment audit and validation scripts.
- Completed Phase 1A authoritative public-data source audit and accession mapping.
- Located, loaded, and read K-Dense `database-lookup` skill instruction `~/.agents/skills/database-lookup/SKILL.md`.
- Logged skill usage in `00_admin/SKILL_USAGE_LOG.tsv`.
- Queried NCBI E-utilities and ENA Portal API for GSE172356, PRJNA723013, SRP315394, and PRJNA719915.
- Reconciled sample and run counts (62 each for host RNA-seq and microbiome metagenomics).
- Established 1-to-1 patient mapping by matching microbiome `source_material_id` with host sample tumor numbers.
- Confirmed library layout for tumor microbiome is single-end WGS shotgun metagenomics (not 16S amplicon).
- Discovered that negative controls (adjacent tissues, environmental, extraction, no-template controls) were only assayed by PCR/gel and not sequenced; no raw control metagenomic reads are available in SRA.
- Downloaded and verified publication supplementary materials (MOESM1-8, including clinical and taxonomic data).
- Created inventories under `01_metadata/`: `accession_inventory.tsv`, `geo_sample_inventory.tsv`, `microbiome_run_inventory.tsv`, and `supplementary_file_inventory.tsv`.
- Updated decision log (`09_docs/planning/DECISION_LOG.md`) with D-05.
- Completed Phase 1B patient-level metadata finalization.
- Populated `01_metadata/sample_manifest.tsv` with 62 unique patient rows.
- Populated `01_metadata/clinical_metadata.tsv` from verified public supplementary metadata only.
- Populated `01_metadata/file_manifest.tsv` for Phase 1 metadata products and downloaded original-study supplementary files.
- Created `01_metadata/rna_microbiome_patient_crosswalk.tsv` with one verified RNA sample and one verified microbiome run per patient.
- Created `04_analysis/02_sample_mapping/PHASE1B_MAPPING_REPORT.md`.
- Verified subtype counts: Basal 17, Classical 22, Hybrid 23.
- Verified overall survival availability for 53 patients; 9 patients lack survival rows in Supplementary Data 4 `Figure3.Survival`.
- Ran `06_scripts/python/00_validate_manifests.py` successfully after manifest population.
- Updated decision log (`09_docs/planning/DECISION_LOG.md`) with D-06.
- Completed Phase 2A processed host expression acquisition and audit using K-Dense `exploratory-data-analysis`.
- Downloaded only the official GEO processed expression matrix `GSE172356_PDA_gene_expression_matrix.txt.gz`; no FASTQ or SRA files were downloaded.
- Created `03_processed/expression/GSE172356_expression_audited.tsv.gz` preserving the original GEO numerical scale.
- Created `03_processed/expression/GSE172356_gene_annotation.tsv` from the source matrix gene identifier column.
- Created `01_metadata/expression_sample_crosswalk.tsv` and mapped all 62 expression columns to the finalized 62-patient manifest.
- Created Phase 2A QC report, tables, and figures under `04_analysis/03_expression_qc/`, `05_results/tables/`, and `05_results/figures/`.
- Identified expression unit as DESeq size-factor-normalized counts based on GEO SOFT processing metadata; marked downstream input-scale confirmation as `TO_VERIFY`.
- Verified matrix dimensions: 45,140 gene rows x 62 expression samples.
- Detected 73,202 missing expression cells, 0 infinite values, 0 negative values, 0 duplicate gene identifiers, 0 duplicate samples, and 15 all-zero genes.
- Flagged four suspected extreme samples by prespecified descriptive QC criteria; no samples were removed.
- Ran `06_scripts/python/00_validate_manifests.py` successfully after Phase 2A file-manifest update.
- Ran `06_scripts/python/03_validate_phase2a_expression.py` successfully.
- Completed Phase 2B missingness audit, filtering sensitivity, transformation, and analysis-ready expression matrix generation.
- Confirmed all 73,202 missing expression cells are literal `NA` strings in the official GEO processed matrix, not blank fields or parse failures.
- Selected complete-observation missing-value handling plus unsupervised expression filtering; retained 42654 genes and all 62 mapped samples.
- Created filtered normalized-count and filtered log2(normalized count + 1) matrices under `03_processed/expression/`.
- Reassessed the four Phase 2A suspected outliers and retained all samples, with sensitivity analysis required for the four flagged samples in later phases.
- Ran `06_scripts/python/04_phase2b_prepare_expression.py` successfully.
- Ran `06_scripts/python/04_validate_phase2b_expression.py` successfully.
- Completed Phase 3A subtype reproduction methods identification, verification, and locking.
- Located, loaded, and read K-Dense `database-lookup`, `citation-management`, and `experimental-design` skill instructions.
- Logged K-Dense skill usages in `00_admin/SKILL_USAGE_LOG.tsv`.
- Audited established PDAC subtyping frameworks (original GSE172356 method, Moffitt, PurIST, Bailey, and Chan-Seng-Yue).
- Extracted PurIST model coefficients and intercept for RNA-seq optimized model (`oct25_equivalent_freeze`).
- Extracted Chan-Seng-Yue 2020 signatures from supplementary workbook.
- Mapped outdated and alternative gene symbols in the Moffitt signature to modern equivalents in the GSE172356 matrix.
- Stored verified signatures under `02_data/reference/PDAC_subtype_signatures/` for original GSE172356, Moffitt, and PurIST frameworks, calculating sizes and MD5/SHA256 checksums.
- Evaluated gene signature coverage in the Phase 2B matrix, writing the coverage report to `05_results/tables/phase3a_signature_gene_coverage.tsv`.
- Created the method inventory at `01_metadata/subtype_method_inventory.tsv`.
- Wrote method lock report `04_analysis/05_subtype_reproduction/PHASE3A_METHOD_LOCK.md` detailing assignment rules, agreement metrics, and sensitivity designs.
- Wrote reproduction protocol `09_docs/methods/PDAC_subtype_reproduction_protocol.md`.
- Updated the project file manifest and decision log with Phase 3A records.
- Completed Phase 3B subtype reproduction without changing locked signatures, coefficients, thresholds, gene-pair directions, or preprocessing rules after inspecting agreement.
- Validated Phase 3B signature runtime status for GSE172356 original, Moffitt, and PurIST methods; all required runtime checks passed.
- Reproduced the primary GSE172356/Chan-Seng-Yue 94-gene subtype labels exactly for all 62 patients: Basal 17, Hybrid 23, Classical 22; exact agreement, balanced accuracy, Cohen's kappa, adjusted Rand index, and normalized mutual information all equal 1.0.
- Applied verified secondary methods only: Moffitt 49-active-gene locked clustering and PurIST 8-pair classifier.
- Generated Phase 3B sample-level assignments, all-method assignments, agreement metrics, confusion matrices, discordance table, sensitivity summary, and five PDF figures under `05_results/`.
- Confirmed no primary discordant samples; binary method behavior for Hybrid samples is reported separately rather than counted as automatic errors.
- Completed sensitivity analyses for all 62 samples, exclusion of `YX16135T`, `YX16158T`, `YX16194T`, and `YX16224T`, log2 median-centering stress test, and non-material alternative missingness stress tests.
- Run `06_scripts/python/05_phase3b_reproduce_subtypes.py` successfully.
- Run `06_scripts/python/05_validate_phase3b_subtypes.py` successfully.
- Wrote Phase 3B report `04_analysis/05_subtype_reproduction/PHASE3B_SUBTYPE_REPRODUCTION.md`.
- Completed Phase 4A prespecification and lock of the PDAC molecular subtype stability analysis framework.
- Read and logged mandatory K-Dense skills `experimental-design` and `statistical-analysis` in `00_admin/SKILL_USAGE_LOG.tsv`.
- Wrote Phase 4A stability method lock report at `04_analysis/06_subtype_stability/PHASE4A_STABILITY_METHOD_LOCK.md` detailing the questions, 12 stability metrics, and multi-statistic discrete cluster decision rules.
- Wrote the step-by-step procedural protocol at `09_docs/methods/PDAC_subtype_stability_protocol.md`.
- Populated the parameters inventory at `01_metadata/subtype_stability_parameter_inventory.tsv` defining 8 distinct primary and sensitivity runs.
- Updated decision log `09_docs/planning/DECISION_LOG.md` with ID `D-11`.
- Completed Phase 4B molecular subtype stability evaluation calculations. Executed all 8 locked stability analyses for K=2..6 with 1,000 resampling iterations, generating tables and figures. Preserved overall stability decision as `INCONCLUSIVE` due to conflict between CSY (preferred K=2) and independent HVGs (preferred K=4), plus transformation sensitivity.
- Completed Phase 5A continuous basal-classical transcriptional axis analysis prespecification and method lock.
- Appended Phase 5A K-Dense skill usage records for `experimental-design` and `statistical-analysis` to `00_admin/SKILL_USAGE_LOG.tsv`.
- Created continuous axis method lock at `04_analysis/07_continuous_subtype_axis/PHASE5A_AXIS_METHOD_LOCK.md` and procedural protocol at `09_docs/methods/PDAC_continuous_axis_protocol.md`.
- Populated the continuous axis parameters inventory at `01_metadata/continuous_axis_parameter_inventory.tsv` locking 6 primary/sensitivity runs.
- Updated decision log `09_docs/planning/DECISION_LOG.md` with ID `D-13`.
- Amended Phase 5A to resolve the Moffitt gene-set inconsistency: created distinct `Moffitt_50_gene_axis.tsv` (25 basal-like, 25 classical, including LEMD1) and `Moffitt_49_gene_axis_no_LEMD1.tsv` (24 basal-like, 25 classical, excluding LEMD1) files, verified 100% coverage in expression matrix, updated parameter inventory with unique IDs (`AXIS_MOFFITT50_PRIMARY` and `AXIS_MOFFITT49_NO_LEMD1_SENSITIVITY`), compiled validation report `PHASE5A_GENESET_RECONCILIATION.md`, and appended decision log entry `D-14`.
- Completed Phase 5B continuous basal-classical transcriptional-axis execution using the amended/re-locked Phase 5A definitions.
- Verified before execution that `AXIS_MOFFITT50_PRIMARY` uses `Moffitt_50_gene_axis.tsv` with 25 Basal-like and 25 Classical genes including `LEMD1`, and that `AXIS_MOFFITT49_NO_LEMD1_SENSITIVITY` uses `Moffitt_49_gene_axis_no_LEMD1.tsv` with 24 Basal-like and 25 Classical genes excluding `LEMD1`; the only signature difference is `LEMD1`.
- Executed all seven locked continuous-axis analysis IDs and generated Phase 5B sample scores, centroid distances, method concordance, public-label descriptive comparisons, ordered-trend tests, Hybrid-state assessments, modality tests, Phase 4B stability integrations, sensitivity summaries, figures, runtime/version records, and validation outputs.
- Applied the locked Phase 5A multi-metric decision rules; Phase 5B overall decision is `INCONCLUSIVE`.
- Created `04_analysis/07_continuous_subtype_axis/PHASE5B_CONTINUOUS_AXIS_RESULTS.md`.
- Created reproducible scripts `06_scripts/R/07_phase5b_continuous_axis.R`, `06_scripts/python/07_summarize_phase5b_axis.py`, and `06_scripts/python/07_validate_phase5b_axis.py`.
- Ran `python3 06_scripts/python/07_validate_phase5b_axis.py` successfully.
- Ran `Rscript 06_scripts/R/07_phase5b_continuous_axis.R` successfully, including validation.
- Completed Phase 6A processed PRJNA719915 tumor microbiome abundance identification, extraction, and audit using K-Dense `database-lookup` and `exploratory-data-analysis`.
- Identified Supplementary Data 1 `42003_2021_2557_MOESM4_ESM.xlsx`, sheet `Genus-level`, as the exact public table used for the primary extracted processed microbiome abundance matrix.
- Extracted `03_processed/microbiome/PRJNA719915_microbiome_abundance_audited.tsv.gz` preserving the released numerical scale: 365 genus rows x 62 tumor sample columns.
- Created `01_metadata/microbiome_sample_crosswalk.tsv` mapping all 62 source matrix sample labels to verified project patients, tumor numbers, microbiome BioSamples, and microbiome SRA runs.
- Created Phase 6A microbiome sample QC, taxon QC, taxon prevalence, potential contaminant-flag, and technical-metadata association tables under `05_results/tables/`.
- Created five descriptive QC figures under `05_results/figures/phase6a_*.pdf`.
- Wrote `04_analysis/04_microbiome_qc/PHASE6A_MICROBIOME_DATA_AUDIT.md`, including source provenance, abundance unit, final dimensions, mapping success, zero inflation, prevalence structure, extreme samples, contamination-control limitations, compositional-analysis suitability, and Phase 6B preprocessing candidates.
- Ran `python 06_scripts/python/08_phase6a_microbiome_audit.py` successfully.
- Ran `python 06_scripts/python/08_validate_phase6a_microbiome.py` successfully.
- Verified Phase 6A constraints: exactly 62 unique tumor samples, one microbiome profile per patient, no duplicated samples, no duplicated taxonomic identifiers, no unmatched patients, no negative values, no missing or infinite values, and rows-as-genera/columns-as-samples orientation.
- Completed Phase 6B: locked and amended the tumor microbiome preprocessing, compositional transformation, and contamination-sensitivity framework. Created parameter inventory (`01_metadata/microbiome_preprocessing_parameter_inventory.tsv`), filtering candidate summary table (`05_results/tables/phase6b_filtering_candidate_summary.tsv`), method lock (`04_analysis/04_microbiome_qc/PHASE6B_MICROBIOME_METHOD_LOCK.md`), and standard operating procedure protocol (`09_docs/methods/PDAC_microbiome_preprocessing_protocol.md`). Predefined cohort-specific pseudocounts, matrix total-abundance proxy technical covariates, locked MaAsLin2 configurations (`normalization = "NONE"`, `transform = "NONE"`), and PERMANOVA/PERMDISP dispersion controls. Defined objective extreme-sample policies and evidence-based contamination categories for 21 flagged genera. Set overall decision status to `READY_WITH_CONTAMINATION_LIMITATIONS`.
- Completed Phase 6C: executed the locked primary microbiome preprocessing rule (`>0` abundance detected in at least 20% of 62 samples), retaining 122 genera and all 62 samples.
- Created primary analysis-ready matrices: `03_processed/microbiome/PRJNA719915_genus_primary_filtered.tsv.gz`, `03_processed/microbiome/PRJNA719915_genus_primary_CLR.tsv.gz`, and `03_processed/microbiome/PRJNA719915_primary_aitchison_distance.tsv.gz`.
- Applied the locked primary pseudocount `0.889651`, verified CLR sample sums near zero, and validated the 62 x 62 Aitchison distance matrix for symmetry, zero diagonal, finite values, and non-negative distances.
- Generated sensitivity representations under `03_processed/microbiome/sensitivity/` for 10% prevalence, 30% prevalence, abundance threshold >10, pseudocounts 0.1 and 1.0, robust CLR, presence/absence Jaccard, high-risk contaminant exclusion, high- plus moderate-risk contaminant exclusion, and exclusion of the three locked technical extreme samples.
- Created Phase 6C contamination-flag table, sample QC table, taxon QC table, matrix inventory, preprocessing sensitivity concordance table, warnings table, six neutral PDF figures, and report `04_analysis/04_microbiome_qc/PHASE6C_ANALYSIS_READY_MICROBIOME.md`.
- Created reproducible scripts `06_scripts/R/09_phase6c_prepare_microbiome.R`, `06_scripts/python/09_phase6c_prepare_microbiome.py`, `06_scripts/python/09_summarize_phase6c_microbiome.py`, and `06_scripts/python/09_validate_phase6c_microbiome.py`.
- Ran `python3 06_scripts/python/09_phase6c_prepare_microbiome.py` successfully.
- Ran `python3 06_scripts/python/09_validate_phase6c_microbiome.py` successfully.
- Completed Phase 7A: prespecified and locked the statistical framework for tumor microbiome and PDAC transcriptional state associations under covariate limitations.
- Located, loaded, and read K-Dense `experimental-design` and `statistical-analysis` skill instructions, logging usage records in `00_admin/SKILL_USAGE_LOG.tsv`.
- Locked the host outcome hierarchy (primary continuous Moffitt50 contrast, secondary coactivation score, and sensitivity outcomes).
- Prespecified global community-level PERMANOVA (9,999 permutations, seed 2026, marginal/sequential sums of squares) and dispersion checks (PERMDISP).
- Predefined genus-level primary OLS models (122 tests, CLR genus abundance against standardized Moffitt50 contrast with HC3 robust standard errors, BH FDR q < 0.05).
- Locked supporting association methods (Spearman correlation, permutation-based tests, bootstrap confidence intervals, MaAsLin2 with normalization=NONE and transform=NONE).
- Locked the regression model hierarchy (Model 0, Model 1, Model 2) and evaluated clinical sensitivity feasibility, blocking Model 2 due to 100% missing data (0 complete cases).
- Predefined contamination sensitivity checks (excl. high/moderate risk contaminants, LOGO, total abundance proxy correlation) and preprocessing sensitivities (9 pre-computed matrices).
- Locked presence/absence logistic regression orientation and sample size constraints (prevalence between 16.1% and 83.9% of cohort).
- Predefined internal evidence classification categories (ROBUST, SUGGESTIVE, METHOD_SENSITIVE, CONTAMINATION_SENSITIVE, NO_SUPPORTED_ASSOCIATION, TO_VERIFY).
- Locked sample-level influence diagnostics (Cook's distance, DFBETAs, leave-one-sample-out).
- Set overall readiness decision status as `READY_WITH_COVARIATE_LIMITATIONS`.
- Created method lock `04_analysis/08_host_microbiome_integration/PHASE7A_MICROBIOME_ASSOCIATION_METHOD_LOCK.md`.
- Created SOP protocol `09_docs/methods/PDAC_microbiome_continuous_state_association_protocol.md`.
- Created parameter inventory `01_metadata/microbiome_association_parameter_inventory.tsv` with 26 analysis rows.
- Created feasibility table `05_results/tables/phase7a_model_matrix_feasibility.tsv`.
- Created feasibility table `05_results/tables/phase7a5_host_covariate_qc.tsv`.
- Completed Phase 7A.5 host-derived tumor purity, immune, and stromal covariate calculation and validation without performing microbiome association tests.
- Installed and used the official MD Anderson/R-Forge ESTIMATE R package `estimate` 1.0.13 through `06_scripts/R/10_phase7a5_host_covariates.R`.
- Generated `01_metadata/host_tme_covariates.tsv` for all 62 patients with stromal score, immune score, ESTIMATE score, and inferred tumor purity; validated 62 unique patients, no duplicated patients, no missing/infinite scores, and exact expression crosswalk order.
- Generated Phase 7A.5 QC outputs: `phase7a5_host_covariate_qc.tsv`, `phase7a5_host_covariate_correlations.tsv`, `phase7a5_covariate_model_feasibility.tsv`, and two PDF figures.
- Determined that Model 3P, Model 3I, and Model 3S are permitted as sensitivity models only; blocked combined adjustment for purity, immune, stromal, and ESTIMATE score due to severe collinearity.
- Updated the Phase 7A lock, microbiome association SOP, and parameter inventory to add only the feasible Phase 7A.5 sensitivity models. Model 0 remains primary.
- Wrote `04_analysis/08_host_microbiome_integration/PHASE7A5_HOST_COVARIATES.md`.
- Ran `Rscript 06_scripts/R/10_phase7a5_host_covariates.R` successfully.
- Ran `python3 06_scripts/python/10_validate_phase7a5_host_covariates.py` successfully.
- Completed Phase 7B: executed the locked continuous association framework between tumor microbiome composition and PDAC transcriptional states. Generated OLS HC3 regressions, PERMANOVA/PERMDISP, Spearman, permutation, bootstrap, covariate sensitivities, preprocessing sensitivities, presence/absence models, sample influence diagnostics, and secondary outcomes.
- Completed Phase 7C: independent statistical and implementation review of the Phase 7B microbiome-host integration analysis. Verified all 33 primary FDR-significant candidates, verified the global PERMANOVA community analysis, verified CLR recomputations, audited sample leverage and covariate models, accepted the MaAsLin2 unavailability (Option A), and generated independent review outputs with a PASS decision.
- Completed Phase 8A: prespecified and locked the host-mechanism analysis framework for the verified tumor-microbiome associations. Located, loaded, and read K-Dense experimental-design, statistical-analysis, and citation-management skills, logging usage in 00_admin/SKILL_USAGE_LOG.tsv. Predefined the five host feature layers, circularity safeguards, OLS HC3 models, sensitivity controls, multi-taxon shared-mechanism integration, evidence categories, and literature guardrails. Locked defaults and set the overall readiness decision to READY_WITH_TRANSFORMATION_LIMITATIONS.
- Completed Phase 8A.5: prepared and validated the project-specific R environment for locked Phase 8B host-mechanism analyses without executing host-mechanism association tests. Created `renv.lock`, initialized project-local `renv`, installed and validated `decoupleR`, `progeny`, `dorothea`, `viper`, `WGCNA`, `GSVA`, `msigdbr`, `limma`, `edgeR`, `matrixStats`, `dynamicTreeCut`, `fastcluster`, `clusterProfiler`, `ReactomePA`, `fgsea`, `tidyverse`, `data.table`, `BiocParallel`, `sandwich`, and `lmtest`. Validated MSigDB Hallmark retrieval, synthetic Hallmark scoring, synthetic PROGENy/decoupleR activity calculation, DoRothEA A/B/C regulon loading, TF activity calculation, WGCNA network construction, limma modeling, HC3 robust standard errors, and R object save/reload. Updated Phase 8 feasibility status to executable for all host-feature layers, with WGCNA memory/runtime TO_VERIFY caveat and a recommendation to use blockwise/vectorized implementations where appropriate.
- Completed Phase 8B: executed locked host-mechanism analyses for the nine Phase 7C-verified primary taxa. Generated Hallmark, PROGENy, DoRothEA/VIPER, WGCNA, genome-wide limma, ranked enrichment, sensitivity, shared-mechanism, evidence, figure, validation, and report outputs under the Phase 8A rules.
- Completed Phase 8C: performed independent statistical, implementation, and evidence review of the completed Phase 8B host–microbiome mechanism analysis. Verified all 43 robust evidence rows, WGCNA parameters, and genome-wide models. Updated status, decision log, and file manifest, and approved proceeding to Phase 9 external-validation planning.
- Completed Phase 9A: external validation planning and dataset qualification.
- Located, loaded, and read K-Dense database-lookup, citation-management, experimental-design, and statistical-analysis skill instructions.
- Appended Phase 9A skill usage records to 00_admin/SKILL_USAGE_LOG.tsv.
- Identified and evaluated 12 candidate external datasets across four validation layers (bulk, single-cell, spatial, and microbiome).
- Created external validation dataset inventory at 01_metadata/external_validation_dataset_inventory.tsv.
- Created parameter inventory at 01_metadata/external_validation_parameter_inventory.tsv locking bulk, single-cell, spatial, and microbiome analyses.
- Created dataset shortlist at 05_results/tables/phase9a_external_dataset_shortlist.tsv, designating 7 PRIORITY_1 datasets for download in Phase 9B.
- Created signature coverage feasibility table at 05_results/tables/phase9a_signature_external_coverage_feasibility.tsv, confirming >=87% coverage across all priority datasets.
- Created analysis resource estimate at 05_results/tables/phase9a_external_analysis_resource_estimate.tsv.
- Compiled validation bibliography and source audit files at 09_docs/references/phase9_external_validation_sources.bib and 09_docs/references/phase9_external_validation_source_audit.tsv.
- Wrote prospective method lock report 04_analysis/09_external_validation/PHASE9A_EXTERNAL_VALIDATION_METHOD_LOCK.md.
- Wrote validation protocol 09_docs/methods/PDAC_external_validation_protocol.md.
- Verified Phase 9A readiness status as READY_WITH_MICROBIOME_LIMITATIONS.
- Completed Phase 9B1: executed locked independent bulk-transcriptome validation using only PRIORITY_1 bulk-host cohorts.
- Read and logged mandatory K-Dense `database-lookup`, `exploratory-data-analysis`, and `statistical-analysis` skills before Phase 9B1 execution.
- Downloaded processed bulk expression matrices and required metadata first under `02_data/external/phase9_bulk/`; no FASTQ, BAM, SRA, single-cell, spatial, or microbiome validation data were downloaded.
- Verified locked cohort sample counts after tumor-only filtering: TCGA_PAAD 178, GSE71729 145, and GSE62452 69.
- Created Phase 9B1 QC, signature coverage, state score, host feature score, module transfer coverage, cohort replication, negative-control, cross-cohort synthesis, and evidence-classification tables under `05_results/tables/phase9b1_*`.
- Created Phase 9B1 PDF figures under `05_results/figures/phase9b1_*.pdf`.
- Wrote `04_analysis/09_external_validation/PHASE9B1_BULK_EXTERNAL_VALIDATION_RESULTS.md`.
- Created reproducible scripts `06_scripts/R/14_phase9b1_bulk_validation.R`, `06_scripts/python/14_prepare_phase9b1_bulk_data.py`, and `06_scripts/python/14_validate_phase9b1_bulk_validation.py`.
- Ran `python3 06_scripts/python/14_validate_phase9b1_bulk_validation.py` successfully.
- Ran `RENV_CONFIG_SANDBOX_ENABLED=false Rscript 06_scripts/R/14_phase9b1_bulk_validation.R` successfully.
- Phase 9B1 evidence summary: no locked Hallmark pathway met external-replication criteria; transferred module signatures MEblack, MEblue, MEgreen, and MEred met external-replication criteria; TF proxy outputs remain `TO_VERIFY` because full decoupleR/VIPER external TF activity scoring was not executable in this managed environment.
- Completed Phase 9B1C: performed independent statistical and implementation review of the bulk-transcriptome external validation. Verified cohort independence, audited PurIST, pathways, modules, and TFs, and identified 6 implementation findings (1 Critical, 4 Major, 1 Moderate). Reapplied evidence classification rules under proper coverage filtering and proxy constraints, and reported the FAIL_REQUIRES_REANALYSIS decision.
- Completed Phase 9B1R: corrected and reran the independent bulk-transcriptome external validation after the Phase 9B1C audit.
- Marked the original Phase 9B1 report `SUPERSEDED_BY_PHASE9B1R` and preserved it only as an audit artifact.
- Reused only the three Phase 9A-qualified bulk cohorts: TCGA_PAAD, GSE71729, and GSE62452; no single-cell, spatial, microbiome, survival, target-prioritization, causal-mediation, or manuscript analyses were performed.
- Corrected PurIST scoring with all locked pair terms, intercept beta0 = -6.815, logistic transformation, no cohort refitting, and the locked cutoff; runtime validation passed for all three cohorts, including GSE62452 with 7/8 pair coverage.
- Replaced invalid Hallmark proxy scores with decoupleR ssGSEA using MSigDB Hallmark 2026.1.Hs full available gene sets.
- Replaced TF-symbol proxy scoring with DoRothEA A/B/C regulon coverage checks and decoupleR/VIPER activity scoring where eligible; TF evidence categories are now derived programmatically from the saved statistics and match the locked Phase 9B1C2 audit counts (12 externally replicated, 13 partially replicated, 9 not replicated, 0 TO_VERIFY).
- Enforced the locked 80% module coverage threshold; GSE71729 and GSE62452 module validations were excluded for low coverage rather than counted as biological failures.
- Executed locked negative controls: patient-label permutation, gene-label permutation, size-matched randomized modules, expression-matched randomized modules, and unrelated Hallmark controls where applicable.
- Wrote Phase 9B1R correction log, corrected report, runtime validation tables, corrected replication/evidence tables, and seven corrected figures under `phase9b1r_*`.
- Ran `python3 06_scripts/python/14_validate_phase9b1r_bulk_validation.py` successfully.
- Completed Phase 9B1C2 independent review of corrected Phase 9B1R bulk external validation results.
- Verified correction of all six previous findings (FIND_01 to FIND_06).
- Generated audit tables phase9b1c2_correction_verification.tsv, phase9b1c2_host_feature_audit.tsv, phase9b1c2_module_coverage_audit.tsv, phase9b1c2_negative_control_audit.tsv, and phase9b1c2_review_findings.tsv.
- Verified and completed the Phase 9B1C2 minor correction concerning FIND_05 and FIND_07 TF evidence classification.
- Confirmed that the hardcoded blanket TO_VERIFY TF assignment has been removed, and categories are derived programmatically matching the locked Phase 9A evidence rules (12 EXTERNALLY_REPLICATED_HOST_FEATURE, 13 PARTIALLY_REPLICATED_HOST_FEATURE, 9 NOT_REPLICATED, 0 TO_VERIFY).
- Verified that the validator fails if blanket TO_VERIFY is assigned.
- Issued the final closure decision of PASS for Phase 9B1C2.
- Initiated Phase 9B2 cellular-source evaluation of externally replicated TF activities and partially replicated or discovery-supported host programs.
- Read and logged mandatory K-Dense `database-lookup`, `exploratory-data-analysis`, and `statistical-analysis` skills before Phase 9B2 startup.
- Reviewed the required locked Phase 9A/9B1R/9B1C2 records and Phase 8C host-mechanism audit context before acquisition.
- Detected a mandatory stop condition: Layer 2 PRIORITY_1 single-cell cohort records disagree across the full inventory, shortlist, and parameter inventory.
- Created `01_metadata/phase9b2_single_cell_dataset_inventory.tsv` documenting the blocked cohort records and confirming no files were downloaded.
- Created `04_analysis/09_external_validation/PHASE9B2_SINGLE_CELL_CELLULAR_SOURCE_RESULTS.md` documenting STOPPED_BEFORE_DATA_ACQUISITION.
- Created Phase 9B2 entry-point scripts `06_scripts/python/15_prepare_phase9b2_single_cell.py`, `06_scripts/python/15_validate_phase9b2_single_cell.py`, and `06_scripts/R/15_phase9b2_single_cell_validation.R`.
- Ran `python3 06_scripts/python/15_prepare_phase9b2_single_cell.py`; it returned exit code 2 by design after writing the blocked inventory and reporting the locked-record disagreement.
- Ran `python3 06_scripts/python/15_validate_phase9b2_single_cell.py` successfully for the stopped-state validation.
- Ran `python3 06_scripts/python/00_validate_manifests.py` successfully.
- Restarted Phase 9B2 after Phase 9A.2 provenance correction using the explicit primary execution contract requiring `PENG_CRA001160` only.
- Read and logged mandatory K-Dense `database-lookup`, `exploratory-data-analysis`, and `statistical-analysis` skills before the restart.
- Re-ran pre-acquisition provenance and manifest validation. The general provenance validator passed, but the stricter restart inclusion check failed because `05_results/tables/phase9a2_phase9b2_authoritative_cohort_set.tsv` marks `PENG_CRA001160`, `LIN_GSE154778`, `MONCADA_GSE111672`, and `HWANG_GSE202051` as `included_in_phase9b2=yes`.
- Created `05_results/tables/phase9b2_restart_runtime_validation.tsv` and updated `04_analysis/09_external_validation/PHASE9B2_SINGLE_CELL_CELLULAR_SOURCE_RESULTS.md` to document the mandatory stop before data acquisition.
- No Phase 9B2 biological data acquisition, scoring, pseudobulk modeling, figures, negative controls, or evidence classifications were performed in the restart.
- Executed Phase 9A.3 execution scope correction: separated suitability status from execution authorization, updating the authoritative cohort set and parameter inventory so that only PENG_CRA001160 is authorized for the current primary Phase 9B2 run.
- Corrected the preparation, validator, and consistency scripts to evaluate against `included_in_phase9b2_primary == TRUE`.
- Generated `05_results/tables/phase9a3_phase9b2_execution_scope.tsv` and validation reports.

## Pending Tasks

- Human review of Phase 3B, Phase 4A, Phase 4B, Phase 5A, Phase 5B, Phase 6A, Phase 6B, Phase 6C, Phase 7A, Phase 7A.5, Phase 8A, Phase 8A.5, Phase 8B, Phase 8C, Phase 9A, Phase 9B1, Phase 9B1C, Phase 9B1R, and Phase 9B2 stopped-state products.
- Resolve `TO_VERIFY`: official source documentation does not explain the literal `NA` entries; raw-count reprocessing remains a possible later-phase check if processed-matrix provenance is judged insufficient.
- Resolve `TO_VERIFY`: Bailey and the full Chan-Seng-Yue 100-gene framework remain exploratory/not directly reproducible without a pre-fitted single-sample classifier or exact locked implementation.
- Resolve `TO_VERIFY`: exact Kraken2/Bracken taxonomic database/version and exact normalization formula for the non-integer Supplementary Data 1 microbiome abundance scale.

## Blocking Issues

- None.

## Next Approved Task

- Target Journal Selection (Phase 11I-B).

## Latest Update: 2026-07-04 Phase 11I-A Final QA and Journal Gap Audit

- Completed Phase 11I-A final QA and journal-specific gap audit with final decision PASS.
- Verified presence of all package files (manuscript, figures 1-5, tables S1-S3, legends, checklist, cover letter, references).
- Verified correct callouts and strict adherence to claim-control constraints.
- Logged 11 journal-specific items (word limits, formats, funding, COI) as TO_BE_CONFIRMED.
- Final readiness decision: `READY_FOR_TARGET_JOURNAL_SELECTION`.

## Latest Update: 2026-07-04 Phase 11H Submission Package Assembly

- Completed Phase 11H Submission Package Assembly with final decision PASS.
- Gathered manuscript, figures, tables, and legends into `08_submission/phase11h_submission_package/`.
- Created generic submission checklist and cover letter draft.
- Logged journal-specific requirements as TO_BE_CONFIRMED (e.g. formatting, author signatures, COI form, funding statements, raw data accession).
- Final readiness decision: `READY_FOR_TARGET_JOURNAL_SELECTION`.

## Latest Update: 2026-07-04 Post-Phase 11G Workspace Cleanup Finalization

- Audited untracked files following Phase 11G completion.
- Created audit report `04_analysis/11_manuscript/POST_PHASE11G_WORKSPACE_CLEANUP_AUDIT.md`.
- Deleted temporary agent utility scripts (`update_files.py`, `update_manifest.py`, `update_manifest2.py`).
- Added intermediate analysis model directories to `.gitignore` (`05_results/models/phase4b/` and `05_results/models/phase9b2/`).
- Final readiness decision remains: `READY_FOR_TARGET_JOURNAL_SELECTION`.

## Latest Update: 2026-07-04 Phase 11G Reference and Submission Package

- Completed Phase 11G reference submission and administrative finalization.
- Executed reference callout repair (Phase 11G-R1b), reference verification (Phase 11G-R2), and reference repair (Phase 11G-R3). The final Phase 11G-R3 decision is PASS.
- Verified that manuscript scientific content, biological conclusions, evidence categories, and target rankings were unchanged.
- Registered Phase 11G / 11G-R1 / 11G-R2 / 11G-R3 files into `01_metadata/file_manifest.tsv`.
- Final readiness decision: `READY_FOR_TARGET_JOURNAL_SELECTION`.

## Latest Update: 2026-07-04 Phase 11F Final Claim Audit

- Completed Phase 11F independent final claim audit of the Phase 11E language-edited manuscript.
- Created `05_results/tables/phase11f_claim_audit.tsv`, `05_results/tables/phase11f_prohibited_claim_scan.tsv`, and report `04_analysis/11_manuscript/PHASE11F_FINAL_CLAIM_AUDIT.md`.
- Evaluated 15 required computational claim constraints, confirming 100% compliance.
- Final validation script `06_scripts/python/19_validate_phase11f_final_claim_audit.py` passed successfully.
- Final readiness decision: `READY_FOR_TARGET_JOURNAL_SELECTION`.

## Latest Update: 2026-07-04 Phase 11E Language and Format Review

- Completed Phase 11E language and format review, generating the edited manuscript `04_analysis/11_manuscript/PHASE11E_FULL_MANUSCRIPT_LANGUAGE_EDITED.md`.
- Improved manuscript readability, tightened flow, and standardized UK spelling throughout.
- Expanded the Discussion section into three coherent paragraphs, expanded all Figure and Table legends, and added details to the Methods summary.
- Strictly preserved all claim-control constraints, ensuring non-causal microbial associations, partial spatial support for protein secretion, and composition-based target scoring penalties were maintained.
- Created independent review report `PHASE11E_LANGUAGE_FORMAT_REVIEW.md` and edit log `phase11e_language_edit_log.tsv`.
- Developed and ran validation script `19_validate_phase11e_language_format.py` which passes successfully.
- Final readiness decision: `READY_FOR_TARGET_JOURNAL_SELECTION`.

## Latest Update: 2026-07-04 Phase 11D Full Manuscript Assembly

- Completed Phase 11D full manuscript assembly based on the Phase 11B draft and Phase 11C review constraints.
- Integrated all required sections (Title, Abstract, Introduction, Results, Discussion, Limitations, Methods summary, placeholders, and legends).
- Preserved the rule that microbial associations are strictly non-causal and no physical localization is claimed.
- Preserved the PARTIAL_SPATIAL_SUPPORT classification for HALLMARK_PROTEIN_SECRETION.
- Preserved the explicit exclusion of CTCFL/BORIS due to composition sensitivity.
- Created three inventory tables: phase11d_manuscript_section_inventory.tsv, phase11d_figure_legend_inventory.tsv, phase11d_supplementary_table_inventory.tsv.
- Wrote and passed the validation script 06_scripts/python/19_validate_phase11d_full_manuscript.py.
- Final readiness decision: READY_FOR_PHASE11E_LANGUAGE_AND_FORMAT_REVIEW.

## Latest Update: 2026-07-04 Phase 11C Independent Review

- Completed Phase 11C independent manuscript claim-control review of the Phase 11B draft.
- Created 05_results/tables/phase11c_manuscript_review_findings.tsv detailing review of 12 critical domains.
- Created 04_analysis/11_manuscript/PHASE11C_MANUSCRIPT_INDEPENDENT_REVIEW.md with the final report.
- Evaluated causality, localization, spatial validation, target prioritization logic, null findings, and limitations.
- Verified Phase 11B manuscript body was unmodified by Phase 11C.
- Created validator 06_scripts/python/19_validate_phase11c_manuscript_review.py.
- Final readiness decision: READY_FOR_PHASE11D_FULL_MANUSCRIPT_ASSEMBLY.

## Latest Update: 2026-07-04 Phase 11B Manuscript Draft Finalization

- Completed Phase 11B manuscript draft finalization after PASS-approved manual revision without rewriting the manuscript body or changing biological conclusions.
- Created `05_results/tables/phase11b_claim_to_text_trace.tsv`, mapping all 16 major Phase 11A manuscript claims to manuscript sections, source evidence, evidence category, allowed wording, prohibited overstatement, and compliance status.
- Created `06_scripts/python/19_validate_phase11b_manuscript_draft.py`, enforcing CTCFL/BORIS exclusion, anti-causal microbiome language, no microbial localization or physical interaction claims, partial spatial validation wording, required null findings, rCLR and Herbaspirillum limitations, Moncada exploratory status, and traceable evidence coverage.
- Ran the Phase 11B validator successfully.
- Final readiness decision: `READY_FOR_PHASE11C_MANUSCRIPT_INDEPENDENT_REVIEW`.

## Latest Update: 2026-07-04 Phase 10C2 Independent Review

- Completed Phase 10C2 independent review of the corrected Phase 10B-R cross-layer evidence synthesis.
- Verified that all descriptive hardcoded overrides were removed and candidate scores derived programmatically from locked Phase 10A rules.
- Confirmed that every eligible candidate in the Phase 10A inventory was scored.
- Verified that CELL_COMPOSITION_EXPLAINED was appropriately penalized.
- Verified that CTCFL/BORIS was NOT promoted and was correctly penalized.
- Verified that unavailable external database queries correctly reduced confidence without unauthorized hardcoding.
- Verified that HALLMARK_PROTEIN_SECRETION and BHLHE40 were evaluated objectively.
- Generated Phase 10C2 review report `04_analysis/10_target_prioritization/PHASE10C2_CORRECTED_TARGET_PRIORITIZATION_INDEPENDENT_REVIEW.md` and audit tables.
- Final decision: `PASS`. Ready for manuscript drafting.

## Latest Update: 2026-07-04 Phase 10B-R Corrected Reanalysis

- Completed Phase 10B-R corrected cross-layer evidence synthesis and target-prioritization reanalysis after Phase 10C rejected the first Phase 10B attempt.
- Removed hardcoded descriptive target overrides from scoring; all rows are generated from the locked Phase 10A evidence inventory, parameter inventory, and prioritization framework.
- Scored every Phase 10A evidence-inventory candidate, including HALLMARK_PROTEIN_SECRETION, HALLMARK_SPERMATOGENESIS, BHLHE40, CTCFL/BORIS, Ochrobactrum, all WGCNA modules, and negative-control/sensitive taxa.
- Applied the locked high-weight cell-type-specificity penalty to `CELL_COMPOSITION_EXPLAINED` candidates; CTCFL/BORIS, BHLHE40, and HALLMARK_SPERMATOGENESIS are not promoted.
- Generated a reproducible external database audit table for OpenTargets, GTEx, and ChEMBL; gene-symbol rows without local query-result evidence are marked `NOT_RUN_DATABASE_UNAVAILABLE` and are not filled from dictionaries.
- Preserved negative and partial evidence: Ochrobactrum remains discovery-only/no causality; HALLMARK_PROTEIN_SECRETION remains partially spatially supported with null basal-classical spatial-axis association; ineligible WGCNA modules remain ineligible.
- Created `04_analysis/10_target_prioritization/PHASE10BR_CORRECTED_TARGET_PRIORITIZATION_RESULTS.md` and Phase 10B-R audit tables under `05_results/tables/phase10br_*`.
- Ran `06_scripts/python/18_validate_phase10br_synthesis.py`, `06_scripts/python/00_validate_manifests.py`, `06_scripts/python/15_validate_provenance_consistency.py`, and `python3 -m pytest 06_scripts/python/test_phase10br_synthesis.py` successfully.
- Final decision: `READY_FOR_PHASE10C2_INDEPENDENT_REVIEW`.

## Latest Update: 2026-07-04 Phase 10C Independent Review

- Completed Phase 10C independent review of Phase 10B cross-layer evidence synthesis.
- Found that OpenTargets and GTEx queries were not stored reproducibly or executed within the project repository.
- Found that CTCFL was selected via post-hoc reasoning, circumventing the rule that single-cell composition-sensitive features should be penalized in cell-type specificity.
- Found that targets were deprioritized using qualitative descriptors rather than the locked quantitative Phase 10A thresholds.
- Found that HALLMARK_SPERMATOGENESIS was omitted from scoring despite being PARTIALLY_REPLICATED.
- Generated review report `04_analysis/10_target_prioritization/PHASE10C_INDEPENDENT_REVIEW.md`.
- Final decision: `FAIL_REQUIRES_REANALYSIS`.

## Latest Update: 2026-07-04 Phase 10B Execution

- Completed Phase 10B cross-layer evidence synthesis and candidate scoring.
- Logged K-Dense skill usage for `opentargets-database`, `gtex-database`, and `chembl-database`.
- Evaluated candidates against the target prioritization framework.
- Determined that HALLMARK_PROTEIN_SECRETION (MULTI_LAYER_SUPPORTED) is a pan-essential process and non-tractable.
- Determined that BHLHE40 (PARTIALLY_REPLICATED) has broad normal tissue expression (Esophagus, Skin, Vagina) and lacks high-quality binding pockets.
- Identified CTCFL (PARTIALLY_REPLICATED) as the most viable biological target due to its exquisite tumor-versus-normal selectivity (GTEx Testis median TPM 7.6 vs <0.1 in all other tissues).
- Created `05_results/tables/phase10b_candidate_target_scores.tsv` and report `04_analysis/10_target_prioritization/PHASE10B_TARGET_PRIORITIZATION_RESULTS.md`.
- Ran `06_scripts/python/18_validate_phase10b_synthesis.py` successfully.
- Final decision: `READY_FOR_MANUSCRIPT_DRAFTING`.

## Latest Update: 2026-07-04 Phase 10A Planning

- Completed Phase 10A prospective cross-layer evidence-synthesis and target-prioritization planning.
- Logged K-Dense statistical-analysis skill usage. (experimental-design, citation-management, and database-lookup skills were unavailable).
- Locked a 10-level cross-layer evidence hierarchy distinguishing primary discovery, external replications, sensitivity, and data sufficiency.
- Preserved locked conclusions: Ochrobactrum robust host-mechanism support only; microbiome causality not validated; HALLMARK_PROTEIN_SECRETION malignant-cell and spatial-compartment enriched but axis-association not replicated; spatial evidence is PARTIAL_SPATIAL_SUPPORT; WGCNA modules not promoted due to insufficient data.
- Designed independent target-prioritization framework (druggability, dependency, selectivity, pathway position, cell-type specificity, safety).
- Created method lock `04_analysis/10_target_prioritization/PHASE10A_CROSS_LAYER_SYNTHESIS_METHOD_LOCK.md` and protocol `09_docs/methods/PDAC_cross_layer_synthesis_protocol.md`.
- Generated inventories under `01_metadata/` and `05_results/tables/`.
- Executed validation scripts successfully.
- Final decision: `READY_FOR_PHASE10B_CROSS_LAYER_SYNTHESIS`.

## Latest Update: 2026-07-03 Phase 9B2 Primary Run and Phase 9B2C Review

- Completed Phase 9B2C independent review on 2026-07-03. Reported a FAIL_REQUIRES_REANALYSIS decision because of unexecuted negative controls and coverage violations.
- Restarted Phase 9B2 from corrected Phase 9A.3 canonical dataset definitions and did not reuse biological results from the stopped attempt.
- Executed primary Layer 2 single-cell cellular-source evaluation for PENG_CRA001160 only (CRA001160, PRJCA001063, Peng et al. 2019).
- Downloaded only processed files from the official CNCB GSA source: count-matrix.txt, all_celltype.txt, and md5sum.txt; no FASTQ or BAM files were acquired.
- Analyzed 57,530 cells from 24 PDAC tumor patients and 11 control pancreas donors.
- Constructed patient-aware pseudobulks and scored locked Moffitt, Hallmark, transferred WGCNA module, and DoRothEA/VIPER TF activity features without TF-expression proxies or new WGCNA reconstruction.

- Restarted Phase 9B2 from corrected Phase 9A.3 canonical dataset definitions and did not reuse biological results from the stopped attempt.
- Executed primary Layer 2 single-cell cellular-source evaluation for `PENG_CRA001160` only (`CRA001160`, `PRJCA001063`, Peng et al. 2019).
- Downloaded only processed files from the official CNCB GSA source: `count-matrix.txt`, `all_celltype.txt`, and `md5sum.txt`; no FASTQ or BAM files were acquired.
- Analyzed 57,530 cells from 35 patients/donors: 24 PDAC tumor patients and 11 control pancreas donors.
- Constructed patient-aware pseudobulks and scored locked Moffitt, Hallmark, transferred WGCNA module, and DoRothEA/VIPER TF activity features without TF-expression proxies or new WGCNA reconstruction.
- Generated Phase 9B2 tables, figures, report, and validators. Negative-control permutation and expression-matched null items remain labelled `TO_VERIFY`.
- Completed Phase 9B2C2: performed independent statistical, implementation, annotation, biological-replicate, negative-control, and evidence review of the corrected Phase 9B2R primary single-cell cellular-source analysis. Verified that findings FIND_01, FIND_02, and FIND_03 are fully resolved and closed, and that all 64 applicable negative controls have been executed. Issued a final review decision of PASS and authorized transition to Phase 9B3 spatial-validation planning. Generated 11 audit tables under 05_results/tables/phase9b2c2_* and the review report 04_analysis/09_external_validation/PHASE9B2C2_CORRECTED_SINGLE_CELL_INDEPENDENT_REVIEW.md.

## Latest Update: 2026-07-03 Phase 9B3B Spatial-Transcriptomic Validation

- Completed Phase 9B3B prospective spatial-transcriptomic validation using the Phase 9B3A/A.1/A.2 locked plan.
- Downloaded official processed spatial files and metadata for `GSE199102`/Hwang and `GSE111672`/Moncada only. No FASTQ or BAM files were acquired; `GSE111672_RAW.tar` was used only to extract processed ST section matrices and associated processed archive contents.
- Preserved Hwang patient, section, ROI, segment, compartment, and paired-segment identifiers. Hwang naive and treated cohorts were analyzed separately, and GeoMx and ST expression matrices were not pooled.
- Official processed usable counts were: Hwang naive 13 patients, 13 sections, 127 ROIs, and 373 segments; Hwang treated 7 patients, 7 sections, 67 ROIs, and 197 segments; Moncada 2 patients, 6 sections, and 3,119 parsed spots. These usable processed counts differ from locked planning estimates and are documented as an execution limitation rather than a blocker.
- Hwang naive primary protein-secretion results showed strong compartment localization in tumor segments by Model A (`is_tumor` beta 0.047949, q = 5.89e-52), but no significant tumor-only Moffitt50 axis association by Model B (beta 0.003517, q = 0.324) and no significant paired tumor-minus-stroma axis association by Model C (beta 0.002433, q = 0.462). Evidence category: `PARTIAL_SPATIAL_SUPPORT`.
- Hwang treated sensitivity showed tumor-segment protein-secretion enrichment by Model A, no significant Model B axis association, and a negative Model C contrast association that was significant but nonconverged.
- Moncada was analyzed only as exploratory cross-platform spatial consistency: 1 of 6 sections had a positive protein-secretion/Moffitt directional association, with no formal population-level replication claim.
- WGCNA modules below 80% spatial feature coverage were classified as `INSUFFICIENT_SPATIAL_DATA`; TF activity was not proxied by TF-symbol expression.
- Phase 9B3B negative-control tables include within-section coordinate permutations, size-matched random gene sets, expression-matched random gene sets where required, unrelated Hallmark pathways, label permutations, and leakage checks.
- Generated Phase 9B3B tables, figure, report, executor, preparation script, and computational validator. Final readiness decision: `READY_FOR_PHASE9B3C_INDEPENDENT_REVIEW`.
